Cancer Diagnostics

FDA Clears Tempus xT CDx to Run as Tumor‑Only Diagnostic

The approval removes the matched‑normal requirement so clinicians can test tumor tissue alone and opens a path for Tempus to migrate its DNA solid‑tumor tests into FDA‑cleared assays under ADLT pricing.